NY-FORTER
4.6.2019 15:21:12 CEST | Business Wire | Press release
Forter , the leader in e-commerce fraud prevention, today announced it has processed a record $100 billion in e-commerce transactions, a milestone no other online fraud decisioning platform has achieved to date. In turn, Forter has increased the dollar amount of processed transactions by 100 times over the past three years, and doubled the amount since January 2019 alone.
By processing massive volumes of transactions, it allows Forter to have the most comprehensive view of both consumer and fraud behavior across enterprises and industries worldwide, including luxury, travel, hospitality, on-demand services, food delivery and digital/e-commerce verticals. Merchants that are part of Forter’s global network—including well-known brands such as Nordstrom, leading online travel companies like Priceline, and fast-growing consumer start-ups such as AWAY Travel—benefit from the sheer size and varied nature of the organizations within this network.
For example, once a credit card is stolen, fraudsters attempt to use the card as much as possible over a short period of time. In order to protect against this, Forter is able to quickly leverage its massive volume of transactional data and award-winning technology to detect potential threats and block them across its global network in a split second, in essence immunizing the entire network—helping to prevent thousands of dollars in losses. Amid regulatory changes around payments and data security, such as GDPR and PSD2, Forter’s ability to detect and prevent fraud throughout the entire customer lifecycle becomes even more valuable to block various types of fraud while meeting regulatory compliance.
In another problematic scenario, users with new credit cards and/or updated address details tend to be at a greater risk of being inaccurately declined by merchants, negatively impacting the purchasing experience. With Forter’s extensive view of consumer behavior, even with updates to payment or personal information, a customer is immediately recognized as legitimate, allowing them to checkout seamlessly. It’s with this large network spanning various industries that Forter is able to protect more organizations and their customers worldwide in a faster and more accurate manner compared to any other fraud prevention provider.
“The reality is, size matters when fighting fraud. With Forter's network being five times the size of the largest global retailer, there is immense power in joining a global coalition of merchants for increased visibility, intelligence and protection, resulting in the ultimate end goal of a frictionless customer experience,” said Michael Reitblat, co-founder and CEO, Forter. “Fraud is unpredictable and chaotic, and merchants need resources to provide accuracy, adaptability and consistency, while remaining consumer-first. Top brands across the globe trust us to help them achieve it all, and today’s $100 billion milestone is a testament to that.”
Forter provides an integrated, identity-based fraud prevention platform that uses advanced machine learning technology and fraud detection capabilities. It delivers the most accurate, real-time and fully automated solution on the market today that is focused on enabling revenue and supporting business performance by solving the following challenges:
- Accuracy --accurately distinguishes legitimate buyers from fraudsters;
- Adaptability --automatically adapts to the dynamic nature of fraud and to new types of purchasing experiences customers demand (ie. BOPIS: buy online, pick-up in store);
- Consistency --delivers a consistent consumer experience from login to check-out. For example, some customers are approved when they check out with a credit card, but if they try and sign up for a loyalty program, they are denied. Consistency is critical to consumer experience.
# # #
About Forter
Forter is the leader in e-commerce fraud prevention, protecting merchants during each stage of the customer lifecycle. The company’s identity-based fraud prevention solution detects instances of fraud and abuse beyond transactions in real-time, such as attempts at account takeover and return abuse.
A team of world-class analysts constantly update Forter’s machine learning solutions with cutting-edge insights and research, ensuring the proprietary algorithms adapt to the latest fraud trends in real-time. As a result, Forter is trusted by Fortune 500 companies, online travel businesses, and fast-growing digital disrupters to deliver exceptional accuracy, a smoother user experience and elevated sales at a much lower cost.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190604005551/en/
Contact:
Angela Whiteford angela.whiteford@forter.com 617-620-2058
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
